Questions from military and public about how well it works
Published:
30 September 2001 y., Sunday
The nation’s only vaccine approved against anthrax has never been a best-seller. The only civilians who ever needed it were ranchers, hide handlers, veterinarians and the few scientists who worked with the deadly soil bacterium.
Sept. 11 changed all that. Doctors’ offices and travel clinics around the country have been swamped with requests for the vaccine amid concern that the tragedies in New York and Washington might foreshadow a bioterrorist attack. More than 1,000 people in the past two weeks have tried to get shots directly from the vaccine’s maker, BioPort of Lansing, Mich. Callers there are being shunted to a recorded message that reflects what doctors everywhere are saying: “All the stockpile that currently exists is owned by the Department of Defense. At this time there is no opportunity for any commercial sales.”
Yet BioPort’s vaccine was until two weeks ago perhaps the most shunned and controversial shot ever produced. For years it has been at the center of a political, medical and legal struggle, with more than 400 members of the military opting to quit or be court-martialed rather than roll up their sleeves.
In May, two Air Force officers filed a federal class action suit, contending that the vaccine should be classified as “investigational” for inhaled anthrax and should be offered only to volunteers who sign informed-consent documents clearly stating they are subjects in an experiment.
Šaltinis:
THE WASHINGTON POST
Copying, publishing, announcing any information from the News.lt portal without written permission of News.lt editorial office is prohibited.
The most popular articles
Plans to coordinate research across Europe on neurodegenerative diseases such as Alzheimer’s and Parkinson’s received strong backing from the European Parliament in a resolution adopted on Thursday.
more »
The WHO team of experts has continued its work in Ukraine over the weekend. While four members continued investigations in Lviv – one of the most affected regions in the country – two others travelled 100 km west of the capital, Kyiv, to Zhytomyr: a medium-sized city and a regional (oblast) capital.
more »
On Wednesday, 4 November 2009, five members of the WHO mission in Ukraine arrived in Lviv, in the western part of the country. Lviv is one of the most affected regions, with more than 100 000 people reportedly sick with influenza-like illness.
more »
The Strategic Advisory Group of Experts (SAGE) on Immunization, which advises WHO on policies and strategies for vaccines and immunization, devoted a session of its 27–29 October meeting to pandemic influenza vaccines.
more »
On 28 October 2009, the Ministry of Health of the Ukraine informed WHO, through its Country Office in Ukraine, about an unusually high level of activity of acute respiratory illness in the western part of the country, associated with an increased number of hospital admissions and fatalities.
more »
The WHO Health in Prisons Project (HIPP) arose in 1995 because of the recognition of the gap between public health and prison health.
more »
The International Day for Disaster Reduction (IDDR) is celebrated every year on 14 October.
more »
On 12 October the EU’s health ministers met in Luxembourg for an extra Council meeting to discuss the new influenza (H1N1).
more »
The European Commission can confirm that on 6 October Commission officials started surprise inspections at the premises of certain companies active in the pharmaceutical industry.
more »
Addressing health experts from throughout the WHO European Region at the 12th European Health Forum Gastein Dr Nata Menabde, Deputy Regional Director at WHO/Europe, explained that the values and commitments in the Tallinn Charter: Health Systems for Health and Wealth are more relevant than ever.
more »